| pubmed-article:15894981 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15894981 | lifeskim:mentions | umls-concept:C0018801 | lld:lifeskim |
| pubmed-article:15894981 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:15894981 | lifeskim:mentions | umls-concept:C0150369 | lld:lifeskim |
| pubmed-article:15894981 | lifeskim:mentions | umls-concept:C0026565 | lld:lifeskim |
| pubmed-article:15894981 | lifeskim:mentions | umls-concept:C0717550 | lld:lifeskim |
| pubmed-article:15894981 | lifeskim:mentions | umls-concept:C1511726 | lld:lifeskim |
| pubmed-article:15894981 | lifeskim:mentions | umls-concept:C0026538 | lld:lifeskim |
| pubmed-article:15894981 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:15894981 | lifeskim:mentions | umls-concept:C0301630 | lld:lifeskim |
| pubmed-article:15894981 | lifeskim:mentions | umls-concept:C2728259 | lld:lifeskim |
| pubmed-article:15894981 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:15894981 | pubmed:dateCreated | 2005-5-16 | lld:pubmed |
| pubmed-article:15894981 | pubmed:abstractText | The CHARM program was designed as 3 separate randomized trials comparing candesartan with placebo in patients with chronic heart failure (CHF) who (1) were intolerant to angiotensin-converting enzyme inhibitor and had left ventricular ejection fraction (LVEF) < or =0.40; (2) were on angiotensin-converting enzyme inhibitor and had LVEF < or =0.40; or (3) had LVEF >0.40. CHARM provides an interesting example of the challenges faced by a Data and Safety Monitoring Committee (DSMC). | lld:pubmed |
| pubmed-article:15894981 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15894981 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15894981 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15894981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15894981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15894981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15894981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15894981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15894981 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15894981 | pubmed:month | May | lld:pubmed |
| pubmed-article:15894981 | pubmed:issn | 1097-6744 | lld:pubmed |
| pubmed-article:15894981 | pubmed:author | pubmed-author:PocockStuartS | lld:pubmed |
| pubmed-article:15894981 | pubmed:author | pubmed-author:HennekensChar... | lld:pubmed |
| pubmed-article:15894981 | pubmed:author | pubmed-author:WilhelmsenLar... | lld:pubmed |
| pubmed-article:15894981 | pubmed:author | pubmed-author:WangDuolaoD | lld:pubmed |
| pubmed-article:15894981 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:15894981 | pubmed:volume | 149 | lld:pubmed |
| pubmed-article:15894981 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15894981 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15894981 | pubmed:pagination | 939-43 | lld:pubmed |
| pubmed-article:15894981 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:meshHeading | pubmed-meshheading:15894981... | lld:pubmed |
| pubmed-article:15894981 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15894981 | pubmed:articleTitle | The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. | lld:pubmed |
| pubmed-article:15894981 | pubmed:affiliation | Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom. | lld:pubmed |
| pubmed-article:15894981 | pubmed:publicationType | Journal Article | lld:pubmed |
